Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Safilo Group SpASAFLF 63 Debt-to-Equity is 0.25 as of Dec. 2025, which is 38% below its 10-year median of 0.40. GuruFocus rates SAFLF with a GF Score™ of 63/100 and a GF Value™ of $1.18 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Safilo Group SpA ranks worse than 52.34% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Safilo Group SpA's Debt-to-Equity or its related term are showing as below:
SAFLF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.18 Med: 0.4 Max: 2.17
Current: 0.25
During the past 13 years, the highest Debt-to-Equity Ratio of Safilo Group SpA was 2.17. The lowest was 0.18. And the median was 0.40.
SAFLF's Debt-to-Equity is ranked worse than 52.34% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs SAFLF: 0.25
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Safilo Group SpA Debt-to-Equity Related Terms
Safilo Group SpA Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Safilo Group SpA's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAFLF vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Safilo Group SpA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Safilo Group SpA Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Safilo Group SpA's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Safilo Group SpA's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Safilo Group SpA (SAFLF) has a Debt-to-Equity of 0.25 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Safilo Group SpA and its competitors. This is 38% below median its historical median of 0.40. Over the past decade, Safilo Group SpA's Debt-to-Equity has ranged from 0.18 to 2.17. According to the industry distribution chart, Safilo Group SpA ranks #369 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 52.3%.
Is Safilo Group SpA's Debt-to-Equity too high?
Safilo Group SpA's current Debt-to-Equity of 0.25 is 38% below median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 2.17. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Safilo Group SpA's value of 0.25 is 8.7% above this industry median. Based on the distribution chart, Safilo Group SpA ranks #369 out of 705 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Safilo Group SpA has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Safilo Group SpA's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Safilo Group SpA ranks #369 out of 705 companies for Debt-to-Equity. This places Safilo Group SpA in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Safilo Group SpA's value of 0.25 is 8.7% above this benchmark. Historically, Safilo Group SpA's own Debt-to-Equity has ranged from 0.18 to 2.17 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 0.23, Safilo Group SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Safilo Group SpA's current Debt-to-Equity of 0.25 is 8.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Safilo Group SpA and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Safilo Group SpA's current Debt-to-Equity is 0.25, which is 38% below median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Safilo Group SpA stock overvalued right now?
Based on GuruFocus' analysis, Safilo Group SpA (SAFLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.18, compared to a current price of $1.86 — trading 57.9% above its estimated fair value. The current Debt-to-Equity is 0.25, which is 38% below median its 10-year median of 0.40 and 8.7% above the Medical Devices & Instruments industry median of 0.23. Safilo Group SpA's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Safilo Group SpA (SAFLF), the current Debt-to-Equity is 0.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Safilo Group SpA (SAFLF) Overvalued in 2026?
Based on GuruFocus' analysis, Safilo Group SpA stock appears to be overvalued.
The current stock price of $1.86 is trading 57.9% above its estimated GF Value™ of $1.18.
GuruFocus considers Safilo Group SpA to be Significantly Overvalued.
Key valuation signals for SAFLF:
Debt-to-Equity: 0.25 (38% below median its 10-year median of 0.40)
GF Value™: $1.18 vs. price of $1.86 (57.9% above fair value)
Industry Position: 8.7% above the Medical Devices & Instruments median (#369 of 705)
No single metric tells the full story. See the SAFLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Safilo Group SpA makes sunglasses and prescription eyewear. It is engaged in design, production, and wholesale distribution of its products through a network of independent distributors and commercial subsidiaries. Its products are sold through the Carrera, Smith, Polaroid and Oxydo brands, as well as a range of other licensed brands. The company operates solely through the wholesale segment channels and divides itself into the following four geographical segments: Europe, America, and Asia. The company earns the majority of its revenue from the Europe business segment.
63GF Score
Get the complete analysis for SAFLF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAFLF has been successfully added to your 
